Loading
Molecular oncologist and Interim Director of the Cancer Research UK Cambridge Institute, known for mapping how the oestrogen receptor drives breast cancer.
Jason Carroll is Interim Director of the Cancer Research UK Cambridge Institute, where he is a Senior Group Leader, and Professor of Molecular Oncology at the University of Cambridge. His laboratory studies oestrogen receptor and FOXA1 transcriptional networks in breast cancer, including the landmark demonstration that differential ER binding patterns predict clinical outcome. His work underpins efforts to overcome endocrine therapy resistance.
| Title | Journal | Year |
|---|---|---|
| Differential oestrogen receptor binding is associated with clinical outcome in breast cancer | Nature | 2012 |
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, HR-positive / HER2-negative breast cancer.
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute and the tags leadership, clinician-scientist.
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.